Connect with a sales representative
Now Approved for CIDP

In adults with chronic inflammatory demyelinating polyneuropathy

Learn about Hizentra for CIDP

Only Hizentra Is the SCIg That Has Provided Safe and Effective PI Protection for Over 7 Years*

The US Phase 3 Trial confirmed the efficacy and tolerability of Hizentra for patients age 2 and older1*

US Phase 3 Study Results1, †

ZERO

Serious bacterial infections (per subject year, annualized rate)

2.76

Any infections (per subject year, annualized rate)

ZERO

Serious adverse reactions§

§Two subjects withdrew from the study due to adverse reactions.
*Demonstrated in patients 2–65 years of age and older in the 12-month US phase 3 trial with Hizentra weekly (n=38). Hizentra has been on the market since 2010.
Hizentra was initiated at a weekly dose of 153% of the previous weekly-equivalent IVIg dose in the US study.
Serious bacterial infections were defined as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
Low rates of lost days of work/school: 2.06 days per subject per year1

A long-term extension study (1.7 years) demonstrated safe, sustained, effective protection from infections2

US Extension Study Results2

ZERO||

Serious bacterial infections (per subject year, annualized rate)

2.38

Any infections (per subject year, annualized rate)

ZERO

Treatment-related serious adverse events#

#Zero subjects discontinued because of treatment-related adverse events.
||During the US extension study, 2 SBIs (bacterial pneumonia) in 2 subjects were reported, giving an annualized rate of 0.06 infections per subject (n=21).
Serious bacterial infections were defined as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

Clinical Perspectives:
Goals of Ig Therapy

Douglas Jones, MD, discusses the goals of Ig therapy and how he works to customize therapy for each patient's unique circumstances.

You are now leaving the current website.

Do you want to continue?

No Yes